Alpha 2.0
Login Register
» Articles » PMID: 5109411

Intrathecal Chemotherapy in Burkitt's Lymphoma

Overview
Journal Br Med J
Specialty General Medicine
Date 1971 Aug 26
PMID 5109411
Citations 12
Authors
J L Ziegler
A Z Bluming
Affiliations
Soon will be listed here.
Abstract

Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt's tumour are described. The response was complete in nearly all patients after the administration of either agent. Cerebrospinal fluid (C.S.F.) remissions were more prolonged in patients receiving intrathecal methotrexate or cytosine arabinoside daily for four days as opposed to a 10-day schedule. A controlled randomized trial of "prophylactic" intrathecal chemotherapy in patients without malignant cells in the C.S.F. on admission showed no protective effect against the subsequent development of malignant pleocytosis. Future therapeutic approaches are considered in the light of these results.

Citing Articles

Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa.

Ozuah N, Lubega J, Allen C, El-Mallawany N Blood Adv. 2020; 4(16):4007-4019.

PMID: 32841337 PMC: 7448606. DOI: 10.1182/bloodadvances.2020002178.

Sixth nerve palsy in sporadic Burkitt Lymphoma.

Yennam S, Kini A, Al Othman B, Lee A Am J Ophthalmol Case Rep. 2019; 16:100565.

PMID: 31737801 PMC: 6849134. DOI: 10.1016/j.ajoc.2019.100565.

Leptomeningeal Carcinomatosis From Carcinoma of Unknown Primary in a Young Patient: A Case Report and a Literature Review.

Moosavi L, DAssumpcao C, Bowen J, Heidari A, Cobos E J Investig Med High Impact Case Rep. 2019; 7:2324709619869380.

PMID: 31423841 PMC: 6699001. DOI: 10.1177/2324709619869380.

Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.

Ngoma T, Adde M, Durosinmi M, Githanga J, AkenOva Y, Kaijage J Br J Haematol. 2012; 158(6):749-62.

PMID: 22844968 PMC: 3431556. DOI: 10.1111/j.1365-2141.2012.09236.x.

Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma.

Petrich A, Sparano J, Parekh S Adv Hematol. 2012; 2012:403648.

PMID: 22570659 PMC: 3337598. DOI: 10.1155/2012/403648.

References
1.
THOMAS L . Pathology of leukemia in the brain and meninges: postmortem studies of patients with acute leukemia and of mice given inoculations of L1210 leukemia. Cancer Res. 1965; 25(9):1555-71. View
2.
Rall D . Conference on obstacles to the control of acute leukemia. Experimental studies of the blood-brain barrier. Cancer Res. 1965; 25(9):1572-7. View
3.
Cooper E, Hughes D, Topping N . Kinetics and chromosome analyses of tissue culture lines derived from Burkitt lymphomata. Br J Cancer. 1966; 20(1):102-13. PMC: 2008046. DOI: 10.1038/bjc.1966.11. View
4.
Rubin R, Ommaya A, HENDERSON E, Bering E, Rall D . Cerebrospinal fluid perfusion for central nervous system neoplasms. Neurology. 1966; 16(7):680-92. DOI: 10.1212/wnl.16.7.680. View
5.
Sullivan M, Vietti T, Fernbach D, GRIFFITH K, HADDY T, WATKINS W . Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs. conventional intrathecal methotrexate. Blood. 1969; 34(3):301-19. View